September 16, 2019
Via E-mail
Roland Sackers
Chief Financial Officer
Qiagen N.V.
Hulsterweg 82
5912 PL Venlo
The Netherlands

       Re:     Qiagen N.V.
               Form 20-F for the Fiscal Year Ended December 31, 2018
               Filed March 6, 2019
               File No. 1-38332

Dear Mr. Sackers:

        We have limited our review of your filing to your contacts with
countries that have been
identified as state sponsors of terrorism, and we have the following comments.
Our review with
respect to this issue does not preclude further review by the Assistant
Director group with respect
to other issues. In our comments, we ask you to provide us with information so
we may better
understand your disclosure.

       Please respond to these comments within ten business days by providing
the requested
information or advise us as soon as possible when you will respond. If you do
not believe our
comments apply to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to these comments, we may have additional
comments.

General

   1. In your letter to us dated August 8, 2016, you discussed contacts with
Syria and Sudan.
      Your website identifies a distributor for Syria. Also, we located a 2018
research journal
      article on the detection of a DNA-damaging carcinogen in plant workers in
Syria which
      reported that, during the study, genomic DNA was isolated from the white
blood cells
      using a DNA Kit from Qiagen, USA, and that DNA concentrations were
measured in the
      biology laboratory at Alassad University Hospital in Damascus, Syria. As
you are aware,
      Syria and Sudan are designated by the U.S. Department of State as state
sponsors of
      terrorism, and are subject to U.S. economic sanctions and/or economic
controls. Please
      describe to us the nature and extent of any past, current, and
anticipated contacts with
      Syria and Sudan since your prior letter, including contacts with their
governments,
      whether through subsidiaries, distributors, affiliates, or other direct
or indirect
      arrangements.
 Roland Sackers
Qiagen N.V.
September 16, 2019
Page 2


      2. Please discuss the materiality of any such contacts with Syria and
Sudan, in quantitative
         terms and in terms of qualitative factors that a reasonable investor
would deem important in
         making an investment decision. Tell us the approximate dollar amounts
of revenues, assets
         and liabilities associated with Sudan and Syria for the last three
fiscal years and the
         subsequent interim period. Address for us the potential impact of the
investor sentiment
         evidenced by divestment and similar initiatives that have been
directed toward companies
         that have operations associated with U.S.-designated state sponsors of
terrorism.

         We urge all persons who are responsible for the accuracy and adequacy
of the disclosure
in the filing to be certain that the filing includes the information the
Securities Exchange Act of
1934 and all applicable Exchange Act rules require. Since the company and its
management are
in possession of all facts relating to a company's disclosure, they are
responsible for the accuracy
and adequacy of the disclosures they have made.

        You may contact Jennifer Hardy, Special Counsel, at (202) 551-3767 or
me at (202) 551-
3470 if you have any questions about the comments or our review.

                                                             Sincerely,

                                                             /s/ Cecilia Blye

                                                             Cecilia Blye,
Chief
                                                             Office of Global
Security Risk

cc:      Daniel Follansbee, Esq.
         Mintz, Levin, Cohn, Ferris, Glovsky & Popeo P.C.

         Suzanne Hayes
         Assistant Director